Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease
- Substances:GolimumabGuselkumab
Norway- Participants:18–64 years · 65+ years
- Substances:Golimumab
Rare diseases
Investigational molecules
Locations
NorwayRandomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease
NorwayEfficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1
NorwayStudy of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD
Norway
NorwayPhase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1
NorwayBI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases
NorwayA study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)
NorwayA study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease
NorwayA study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease
NorwayA Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
NorwayA study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy
NorwayTell us about your condition – we search every trial in Europe and connect you with the right site.